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Abstract
Background:  C.E.R.A. (Continuous Erythropoietin Receptor Activator) is an innovative agent with
unique erythropoietin receptor activity and prolonged half-life. This study evaluated C.E.R.A. once weekly
(QW) or once every 3 weeks (Q3W) in patients with anemia and advanced non-small cell lung cancer
(NSCLC) receiving chemotherapy.
Methods: In this Phase II, randomized, open-label, multicenter, dose-finding study, patients (n = 218) with
Stage IIIB or IV NSCLC and hemoglobin (Hb) ≤ 11 g/dL were randomized to one of six treatment groups
of C.E.R.A. administered subcutaneously for 12 weeks: 0.7, 1.4, or 2.1 μg/kg QW or 2.1, 4.2, or 6.3 μg/kg
Q3W. Primary endpoint was average Hb level between baseline and end of initial treatment (defined as
last Hb measurement before dose reduction or transfusion, or the value at week 13). Hematopoietic
response (Hb increase ≥ 2 g/dL or achievement of Hb ≥ 12 g/dL with no blood transfusion in the previous
28 days determined in two consecutive measurements within a 10-day interval) was also measured.
Results:  Dose-dependent Hb increases were observed, although the magnitude of increase was
moderate. Hematopoietic response rate was also dose dependent, achieved by 51% and 62% of patients
in the 4.2 and 6.3 μg/kg Q3W groups, and 63% of the 2.1 μg/kg QW group. In the Q3W group, the
proportion of early responders (defined as ≥ 1 g/dL increase in Hb from baseline during the first 22 days)
increased with increasing C.E.R.A. dose, reaching 41% with the highest dose. In the 6.3 μg/kg Q3W group,
15% of patients received blood transfusion. There was an inclination for higher mean Hb increases and
lower transfusion use in the Q3W groups than in the QW groups. C.E.R.A. was generally well tolerated.
Conclusion: C.E.R.A. administered QW or Q3W showed clinical activity and safety in patients with
NSCLC. There were dose-dependent increases in Hb responses. C.E.R.A. appeared to be more effective
when the same dose over time was given Q3W than QW, with a suggestion that C.E.R.A. 6.3 μg/kg Q3W
provided best efficacy in this study. However, further dose-finding studies using higher doses are required
to determine the optimal C.E.R.A. dose regimen in cancer patients receiving chemotherapy.
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Background
Non-small cell lung cancer (NSCLC) is one of the most
common tumors diagnosed in Western countries. The
predicted incidence of lung cancer in the US was 173,000
new cases in 2005 [1], of which most (over 80%) will
have a diagnosis of NSCLC. The majority of patients with
Stage IIIB (pleural effusion) or Stage IV NSCLC require
chemotherapy as part of their management program,
which is often toxic; current first-line standards of care for
Stage III-IV NSCLC use platinum compounds (such as car-
boplatin or cisplatin) combined with gemcitabine, vinor-
elbine, or taxanes, usually administered in 3-week cycles
[2-5].
The prevalence of anemia (defined as hemoglobin [Hb] <
11 g/dL) in patients with lung cancer ranges from 50% to
60%, and blood transfusions are common, with 30% to
40% of patients requiring this treatment [6,7]. The cause
of cancer-related anemia is often multifactorial. It is asso-
ciated with the excessive release of cytokines such as inter-
leukin-1, tumor necrosis factor, and interferons, which
interfere with the production of endogenous erythropoie-
tin and inhibit erythroid bone marrow production [8,9].
The anemia is also exacerbated by the use of myelosup-
pressive combination chemotherapy, particularly with
platinum compounds [5].
Anemia has a major impact on the quality of life (QoL) of
patients with cancer, its symptoms including fatigue, diz-
ziness, headache, and shortness of breath [10-12]. In
patients with lung cancer, these symptoms are often
enhanced by diminished pulmonary function and the fre-
quent presence of comorbidities [11]. Anemia has also
been shown to be associated with a diminished response
to chemotherapy and a decreased survival in patients with
NSCLC [13-15]. Blood transfusions provide effective
acute relief of anemia, but their effects are short-lived and
they are associated with significant risks such as transfu-
sion reactions and transmission of infection [16,17].
Treatment of chemotherapy-associated anemia with the
erythropoiesis-stimulating agents (ESAs), epoetin alfa,
epoetin beta, and darbepoetin alfa, has been shown to
increase Hb levels, thereby reducing the need for transfu-
sions and improving QoL [18-22]. In anemic patients
with cancer, ESAs were initially administered three-times
weekly, a schedule that had already proved effective in
patients with renal anemia. Recently, there have been
moves towards once weekly (QW) administration with all
ESAs [20,23,24]. Darbepoetin alfa has also been licensed
recently for once every 3 weeks (Q3W) use in anemic
patients receiving chemotherapy for cancer. Given the
increased convenience of once per cycle dosing, it is
important that new agents being developed for the treat-
ment of chemotherapy-induced anemia are studied at
intervals of Q3W.
Continuous Erythropoietin Receptor Activator (C.E.R.A.)
is an innovative agent with unique receptor activity and a
prolonged half-life. It is a chemically synthesized C.E.R.A.
that differs from erythropoietin through the integration of
amide bonds between amino groups and methoxy poly-
ethylene glycolsuccinimidyl butanoic acid [25,26].
C.E.R.A. is currently in development to provide correction
of anemia and stable control of Hb levels at extended
administration intervals in patients with cancer [26,27].
Studies in healthy volunteers demonstrated that C.E.R.A.
had lower systemic clearance and an increased elimina-
tion half-life (t1/2) compared with other ESAs, and supe-
rior potency in vivo with respect to the magnitude and
duration of response [28,29]. Further healthy volunteer
studies demonstrated rapid, dose-dependent increases in
reticulocytes following either intravenous or subcutane-
ous (SC) administration of C.E.R.A. [30]. An exploratory
Phase I–II dose-escalation study in anemic patients with
multiple myeloma receiving myelosuppressive chemo-
therapy (selected as a more responsive population to ESA
treatment based on their baseline ratio of observed/pre-
dicted erythropoietin levels) confirmed the long half-life
of C.E.R.A. (median 6.3–9.7 days) [27]. Also, a dose-
dependent increase in Hb response was observed with
C.E.R.A. doses up to 8 μg/kg when administered Q3W by
SC injection. An Hb increase of ≥ 2 g/dL in the first 6
weeks was achieved in 50.0%–62.5% of patients treated
with C.E.R.A. 3.5–8.0 μg/kg Q3W.
This multicenter, open-label, randomized study was
designed to evaluate the efficacy, safety, and pharmacoki-
netic profile of C.E.R.A. administered SC QW or Q3W to
patients with anemia and advanced (Stage IIIB or IV)
NSCLC receiving chemotherapy. A further aim was to
determine the optimum C.E.R.A. dose. The dose range
chosen was based on that used in the previous study in
multiple myeloma patients [27].
Methods
Patients
Patients eligible for study inclusion were adults (aged ≥ 18
years) with Stage IIIB or IV NSCLC and a Hb level of ≤ 11
g/dL at screening. Patients were receiving first or second
line chemotherapy at screening, which continued for at
least 9 weeks during the study. Additionally, patients had
an Eastern Cooperative Oncology Group (ECOG) per-
formance status grade of 0–2 (first-line chemotherapy) or
0–1 (second-line chemotherapy) and a life expectancy of
> 6 months.Trials 2007, 8:8 http://www.trialsjournal.com/content/8/1/8
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Patients were excluded from the study if they had received
a red blood cell transfusion or radiation therapy in the 4
weeks before the first planned dose of study medication,
or had any active second malignancy within the previous
5 years, excluding basal cell carcinoma and squamous cell
carcinoma of the skin, or cervical carcinoma in situ. Other
exclusion criteria included: brain metastasis; clinically sig-
nificant hypertension; acute or chronic bleeding requiring
treatment within 3 months of the study start; functional
iron deficiency (transferrin saturation < 20% and serum
ferritin < 100 ng/mL); grade 3/4 thrombocytopenia
(platelet count < 50 × 109/L) or thrombocytosis (platelet
count > 500 × 109/L); creatinine > 2.5 mg/dL; C-reactive
protein (CRP) > 50 mg/L; known folic acid/B12 deficiency
or hemolysis; history of seizure, acute infection or inflam-
matory disease; pregnancy or lactation. Patients were also
excluded if they had been treated with ESA therapy in the
8 weeks before study drug administration and were
known to have resistance to ESA administration.
Study design
This was a Phase II, randomized, open-label, multicenter,
dose-finding study where patients were planned to receive
C.E.R.A. SC injections over a 12-week treatment period.
The design and conduct of the study complied with the
principles of good clinical practice, in accordance with the
Declaration of Helsinki. The study was approved by local
ethics committees and informed written consent was
obtained from all patients before enrollment.
C.E.R.A. administration and dose adjustment
Eligible patients were randomized to one of six treatment
groups in two dose schedules: C.E.R.A. 0.7, 1.4, or 2.1 μg/
kg QW or C.E.R.A. 2.1, 4.2, or 6.3 μg/kg Q3W. Patients
received the first dose of study drug not more than 14 days
after they were screened. The first dose of C.E.R.A. was
given on day one of the cycle, before the administration of
cyclic chemotherapy. Dose changes were made based
upon the Hb levels on dosing day (within 24 hours). No
dose increases of C.E.R.A. were allowed. If the Hb level
increased by > 2 g/dL within 2 weeks, or if the Hb was >
12 g/dL and ≤ 13 g/dL, the current dose was reduced by
50%. Instructions were given to the investigators to reduce
the dose only once during the study, when these criteria
were met. Treatment was withheld if the Hb level was > 13
g/dL until a value of ≤ 12 g/dL was achieved. Treatment
was then resumed at 50% of the previous dose. If the Hb
level was > 14 g/dL, patients were evaluated for appropri-
ate clinical intervention (for example, phlebotomy or use
of fluids if hydration was considered necessary).
Assessments
Hematology parameters, vital signs, and body weight
were measured at screening and weekly thereafter. Blood
samples for pharmacokinetic assessment and laboratory
tests (including blood chemistry and iron parameters)
were taken and assessed at baseline and at regular inter-
vals thereafter. Electrocardiogram (ECG) readings and
anti-C.E.R.A. antibodies were analyzed at weeks 4, 8, 13
(or end of the study), and at a follow-up visit 8 weeks after
the last dose of C.E.R.A. Adverse events, iron supplemen-
tation, blood transfusions, and concomitant medications
were documented throughout the course of the study.
Endpoints
Efficacy
The primary efficacy endpoint was the average Hb level
between baseline and end of initial treatment, defined as
the last Hb measurement before a dose reduction or trans-
fusion, or the value at week 13, whichever came first. Sec-
ondary endpoints included the following parameters: the
Hb response, which was defined as an increase in Hb of ≥
2 g/dL from baseline on two consecutive measurements
within a 10-day interval at any time during the study, with
no blood transfusion in the previous 28 days; the hemat-
opoietic response, which was defined as a Hb response or
achievement of Hb ≥ 12 g/dL at any time during the study,
with no blood transfusion in the previous 28 days.
Changes in Hb, hematocrit, and reticulocyte counts were
assessed over time, together with the requirement for any
blood transfusions.
Two additional analyses not included in the study proto-
col were also performed. First, the average change in Hb
level was assessed from baseline during week 5 to the end
of study (week 13 or last assessment). In the event of
blood transfusion, the last Hb value in the preceding 2
days was carried forward for the next 28 days. Second,
responder categorization was performed as follows: 'early
responders', defined as patients with a ≥ 1 g/dL increase in
Hb from baseline during the first 22 days, with no con-
comitant blood transfusion during the study; 'additional
responders', defined as patients who were not early
responders but achieved the target therapeutic range of
11–13 g/dL during the study without blood transfusion;
'non-responders', defined as patients who did not qualify
as 'early responders' or 'additional responders'.
Pharmacokinetics
Serum concentrations of C.E.R.A. were measured using an
enzyme-linked immunosorbent assay (ELISA) with a limit
of quantification of 150 pg/mL and used to determine the
maximum serum concentration (Cmax) and time to maxi-
mum serum concentration (Tmax). The t1/2 was estimated
for ln(2)/k, where the rate constant of elimination (k) was
determined by linear regression on the logarithm of the
serum concentration versus time data in the post-distribu-
tion phase. The area under the concentration-time curve
(AUC) following C.E.R.A. administration, from pre-dose
on day 22 until the last sampling time at which the con-Trials 2007, 8:8 http://www.trialsjournal.com/content/8/1/8
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centration was measurable (day 29 for the QW group and
day 43 for the Q3W group), was estimated by the linear
trapezoidal rule.
Safety
Safety endpoints included adverse events, clinical labora-
tory tests, vital signs, body weight, physical examination,
and ECGs. The intensities of adverse events and labora-
tory values were graded according to the National Cancer
Institute/National Institutes of Health Common Toxicity
Criteria.
Statistical analyses
A sample size of 210 patients (35 per treatment group)
was calculated to have 90% power in rejecting the overall
F-test of no difference among the three treatment groups
in each dose schedule group in the primary efficacy varia-
ble at the alpha level of 0.025 (2-sided). The 90% power
and 0.025 significance level were chosen to address the
multiple testing of the two-dosing schedule. This sample
size included an anticipated dropout rate of 10%.
The efficacy of study medications was primarily evaluated
for the intent-to-treat (ITT) population, which included
patients who were randomized and received at least one
dose of study medication. A per-protocol (PP) analysis
was also performed, which included patients who met the
inclusion criteria, did not receive blood transfusions dur-
ing the study, and had no major protocol violations that
are known to affect response to ESAs, such as blood trans-
fusions in the 4-week period before first planned dose of
C.E.R.A., functional iron deficiency (serum ferritin < 100
ng/mL and transferrin saturation < 20%), known hemol-
ysis or acute infection or inflammatory disease (CRP > 50
mg/L). Patients with blood transfusions during the study
were not considered protocol violations, but they were
excluded from the PP analysis to avoid the compounding
effect of transfusions on efficacy variables, such as change
in Hb levels. The safety population included all rand-
omized patients who received at least one dose of study
medication.
The primary efficacy variable was the average Hb level
during the period from baseline until the end of initial
treatment (defined as last observed value before a dose
change or blood transfusion) and was based on AUC
using linear trapezoidal rule). This AUC approach was
chosen in consideration of the commonly observed large
variability in Hb measurements, since the cumulative
effects on Hb level are assessed rather than Hb changes at
one or two time points, enabling robust evaluation of bio-
logical activity of the treatment based on the benefits over
the entire course of therapy.  Average Hb level from base-
line to end of initial treatment was analyzed using an
analysis of covariance (ANCOVA) model, with treatment
group as a fixed factor and baseline Hb as a covariate. The
average Hb change from baseline during week 5 until the
end of study (week 13 or last available assessment) was
also analyzed by ANCOVA, as for the primary efficacy var-
iable. Cumulative response rates over time were estimated
by Kaplan–Meier methods. All data, including Hb values
for each assessment visit and pharmacokinetic parame-
ters, were summarized using descriptive statistics.
Results
Patient disposition
A total of 218 patients with NSCLC were enrolled into the
study from 61 centers in North America, Central America,
Europe, Asia, and Australia. Of these, 109 were rand-
omized to one of the QW doses of C.E.R.A.; 36 to the 0.7
μg/kg group, 37 to the 1.4 μg/kg group, and 36 to the 2.1
μg/kg group. The other 109 patients were randomized to
Q3W doses: 37 to the 2.1 μg/kg group, 37 to the 4.2 μg/kg
group, and 35 to the 6.3 μg/kg group. The flow of patients
through the study is shown in Figure 1. One patient in the
QW group (2.1 μg/kg subgroup) and four patients in the
Q3W group (three in the 2.1 μg/kg subgroup and one in
the 6.3 μg/kg subgroup) did not receive any study drug
after randomization and were not included in the ITT, PP,
and safety analysis populations. The mean duration on
study was similar across the six dose groups (74–81 days).
In the QW group, 18 patients were withdrawn from the
study for the following reasons: adverse events (eight
patients), death (six patients), refused treatment (three
patients), and withdrawal at the discretion of the investi-
gator (one patient). In the Q3W group, 24 patients were
withdrawn for similar reasons: death (11 patients),
adverse events (five patients), refused treatment or failed
to return (seven patients), and a site error (one patient,
who was started on third-line treatment [gefitinib] and
the investigator thought the patient had to be withdrawn).
Figure 1 gives the reasons for withdrawal by treatment
group.
In the QW and Q3W groups, five and three further deaths,
respectively, occurred after study completion. All the
deaths were considered by the investigator to be unrelated
to study medication. Overall, 44 and 36 patients in the
QW and Q3W groups, respectively, were excluded from
the PP population, the most common reason being the
need for blood transfusion during treatment in 39 (89%)
and 28 (78%) patients, respectively (Table 1).
Baseline characteristics
The demographics and clinical characteristics at baseline
were comparable among the QW and Q3W treatment
groups (Table 2). The majority of patients had Stage IV
NSCLC and had received chemotherapy before the start of
the study. Approximately one-fifth to one-third ofTrials 2007, 8:8 http://www.trialsjournal.com/content/8/1/8
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Patient flowchart Figure 1
Patient flowchart. 
AEs: adverse events. 
C.E.R.A.: Continuous Erythropoietin Receptor Activator. 
ITT: intent to treat. 
QW: once weekly. 
Q3W: once ever 3 weeks. 
*One patient in the C.E.R.A. 2.1 μg/kg QW group, three patients in the 2.1 μg/kg Q3W group and one patient in the 6.3 μg/kg 
Q3W group were excluded from the ITT and safety analyses because they did not receive any study drug.
Included in 
ITT/safety 
analysis  
(n = 34)* 
Included in 
ITT/safety 
analysis 
 (n = 35)* 
Assessed for 
eligibility 
(n = 414)
Allocated to C.E.R.A. QW
0.7, 1.4, or 2.1 µg/kg  
(n = 109) 
C.E.R.A. QW 
0.7 µg/kg 
(n = 36) 
Excluded (n = 196): 
Inclusion criteria not met (n = 180) 
Refused to participate (n = 6) 
Other reasons (n = 7) 
Randomized
(n = 218) 
Allocated to C.E.R.A. Q3W
2.1, 4.2, or 6.3 µg/kg  
(n = 109)
C.E.R.A. QW 
1.4 µg/kg 
(n = 37) 
C.E.R.A. QW 
2.1 µg/kg 
(n = 36) 
Included in 
ITT/safety 
analysis 
(n = 36) 
Included in 
ITT/safety 
analysis  
(n = 37) 
Discontinued 
(n = 8):  
3 AEs;  
3 deaths;  
1 treatment 
refusal; 
1 investigator 
decision.
Discontinued 
(n = 5): 
3 AEs;  
1 death;  
1 treatment 
refusal. 
Discontinued 
(n = 5):  
2 AEs;  
2 deaths;  
1 treatment 
refusal. 
Discontinued 
(n = 8):  
2 AEs;  
4 deaths;  
1 treatment 
refusal;  
1 failure to 
return.
Discontinued 
(n = 5): 
3 deaths;  
1 treatment 
refusal;  
1 failure to 
return. 
C.E.R.A. Q3W 
2.1 µg/kg 
(n = 37) 
Included in 
ITT/safety 
analysis  
(n = 37) 
C.E.R.A. Q3W 
4.2 µg/kg 
(n = 37) 
C.E.R.A. Q3W 
6.3 µg/kg 
(n = 35) 
Included in 
ITT/safety 
analysis  
(n = 34)* 
Discontinued 
(n = 11): 
3 AEs;  
4 deaths;  
3 treatment 
refusal;  
1 site error. Trials 2007, 8:8 http://www.trialsjournal.com/content/8/1/8
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patients in each dose group had undergone surgery and/
or radiotherapy. The median Hb level at baseline was sim-
ilar among treatment groups, ranging from 10.1 g/dL to
10.6 g/dL (Table 2).
All patients received chemotherapy during the study,
which was most commonly platinum based (carboplatin
and cisplatin; 83%, 59%, and 71% in the 0.7, 1.4, and 2.1
μg/kg QW groups; 91%, 68%, and 65% in the 2.1, 4.2,
and 6.3 μg/kg Q3W groups, respectively). Other most
common chemotherapies included gemcitabine hydro-
chloride (43%–53% in the QW group and 41%–53% in
the Q3W group) and taxanes (28%–46% in the QW group
and 30%–44% in the Q3W group).
Overall, 97 patients received iron therapy and of these
most (87 patients [90%]) received oral iron supplementa-
tion. The proportion of patients receiving intravenous
iron supplementation was similar across all six C.E.R.A.
groups. The percentage of patients receiving concomitant
oral iron supplements was somewhat higher in patients
who received C.E.R.A. Q3W (46% to 53%) than in
patients treated QW (26% to 36%).
Efficacy
Except where stated, all efficacy analyses were conducted
for the ITT population. For the primary endpoint, the
mean Hb change from baseline during the initial treat-
ment period was for the QW group: -0.36 (95% confi-
dence interval [CI]: -0.66 to -0.07), -0.19 (95% CI: -0.48
to +0.10), and -0.06 g/dL (95% CI: -0.36 to +0.24) in the
0.7, 1.4, and 2.1 μg/kg groups, respectively. For the Q3W
group, the mean Hb changes were -0.23 (95% CI: -0.54 to
+0.08), -0.07 (95% CI: -0.37 to +0.23), and 0.28 g/dL
(95% CI: -0.03 to +0.59) in the 2.1, 4.2, and 6.3 μg/kg
groups, respectively. Similar inclinations were observed in
the PP population (mean increases -0.21, -0.08, 0.31 g/dL
for the QW dose groups and 0.07, 0.23, 0.42 g/dL for the
Q3W dose groups, respectively).
As Hb levels declined during the first few weeks of
C.E.R.A. therapy in patients receiving concomitant chem-
otherapy, an additional analysis was performed to deter-
mine the average Hb changes from baseline during weeks
5 and 13 (or last assessment). Dose-dependent increases
in Hb were observed in the QW and Q3W groups, with an
increase of 0.66 g/dL in the 6.3 μg/kg Q3W group (Table
3).
Hb response (defined as two consecutive, within 10-day
increases from baseline Hb by ≥ 2 g/dL not related to
transfusion) was reported for 8%, 22%, and 34% of
patients in the 0.7, 1.4, and 2.1 μg/kg QW groups, respec-
tively, and in 12%, 24%, and 26% of patients in the 2.1,
4.2, and 6.3 μg/kg Q3W groups, respectively. The propor-
tion of patients achieving a hematopoietic response (Hb
response or Hb ≥ 12 g/dL during the study) increased with
increasing C.E.R.A. dose in both groups; 31%, 43%, and
63% of patients in the 0.7, 1.4, and 2.1 μg/kg QW groups,
respectively, and 35%, 51%, and 62% of patients in the
2.1, 4.2, and 6.3 μg/kg Q3W groups, respectively.
The majority of patients did not require blood transfusion
during the study: 64%, 68%, and 60% of patients in the
0.7, 1.4, and 2.1 μg/kg QW groups, respectively, and 62%,
81%, and 85% of patients in the 2.1, 4.2, and 6.3 μg/kg
Table 1: Analysis populations and reasons for exclusion from the per-protocol population.
C.E.R.A. dose group (μg/kg QW) C.E.R.A. dose group (μg/kg Q3W)
0.7 1.4 2.1 2.1 4.2 6.3
Number of patients randomized 36 37 36 37 37 35
Number of patients in ITT/safety population* 36 37 35 34 37 34
Number of patients in PP population 22 23 20 21 27 25
Number of randomized patients excluded from PP population 14 14 16 16 10 10
Reasons for exclusion from PP population**
Blood transfusion during study period 13 12 14 16 7 5
Acute infection/inflammatory disease (CRP > 50 mg/L) 1 4 1 2 3 3
Received no study medication 0 0 1 3 0 1
Blood transfusion during 4-week period before study entry 0 0 0 3 0 0
Inclusion criteria not met 0 0 0 0 0 1
C.E.R.A.: Continuous Erythropoietin Receptor Activator.
CRP: C-reactive protein.
ITT: intent-to-treat.
PP: per-protocol.
QW: once weekly.
Q3W: once every 3 weeks.
*One patient in the C.E.R.A. 2.1 μg/kg QW group, three patients in the 2.1 μg/kg Q3W group and one patient in the 6.3 μg/kg Q3W group were 
excluded from the ITT and safety analyses because they did not receive any study drug.
**Patients may have had more than one reason for being excluded from the PP population.Trials 2007, 8:8 http://www.trialsjournal.com/content/8/1/8
Page 7 of 15
(page number not for citation purposes)
Q3W groups, respectively, remained transfusion-free (Fig-
ure 2). In the 6.3 μg/kg Q3W group, no patient received
more than one blood transfusion.
For the responder categorization analysis carried out on
the Q3W group, a dose-dependent effect was seen in the
proportion of 'early responders' and 'non-responders'
(Figure 3). The proportion of 'additional responders' was
similar in the 2.1 and 4.2 μg/kg groups and lowest in the
6.3 μg/kg group. The magnitude of mean Hb increase dur-
ing weeks 5–13 (or last assessment) was higher in patients
with an 'early response' than in those who had 'no
response' regardless of the C.E.R.A. dose (-0.2 versus -1.1
g/dL in the 2.1 μg/kg group; 2.4 versus -1.5 g/dL in the 4.2
μg/kg group; 1.7 versus -1.2 g/dL in the 6.3 μg/kg group).
However, these differences should be viewed with cau-
Table 3: Average hemoglobin changes from baseline during weeks 5–13 (or last assessment): intent-to-treat population.
C.E.R.A. dose group, μg/kg n Least squares mean (95% CI)* Hb change (g/dL)
QW
0.7 31 -0.24 (-0.79 to +0.31)
1.4 35 0.02 (-0.49 to +0.54)
2.1 34 0.40 (-0.12 to +0.93)
Q3W
2.1 31 -0.16 (-0.75 to +0.42)
4.2 36 0.19 (-0.35 to +0.73)
6.3 33 0.66 (0.09 to +1.22)
C.E.R.A.: Continuous Erythropoietin Receptor Activator.
Hb: hemoglobin.
QW: once weekly.
Q3W: once every 3 weeks.
*Derived from analysis of covariance including dose group (QW and Q3W separately) as a fixed factor and the baseline value as a covariate in the 
model.
CI: confidence interval.
Table 2: Summary of patients' baseline characteristics (median values, except where indicated): safety population.
C.E.R.A. dose group (μg/kg QW) C.E.R.A. dose group (μg/kg Q3W)
0.7 1.4 2.1 2.1 4.2 6.3
Number of patients randomized 36 37 36 37 37 35
Sex, n, (%)
Male 23 (64) 22 (59) 26 (72) 22 (59) 20 (54) 28 (80)
Female 13 (36) 15 (41) 10 (28) 15 (41) 17 (46) 7 (20)
Age, y (range) 66 (52–80) 65 (41–83) 66 (50–83) 63 (41–91) 63 (24–84) 64 (33–81)
Body weight, kg (range) 71 (41–127) 70 (39–102) 71 (41–91) 66 (36–90) 66 (39–89) 72 (47–100)
Disease stage, n, (%)
IIIB 9 (25) 10 (27) 9 (26) 13 (38) 11 (30) 4 (12)
IV 27 (75) 27 (73) 26 (74) 21 (62) 26 (70) 30 (88)
Previous treatment before study entry, n, (%)
Chemotherapy 32 (89) 35 (95) 30 (86) 33 (97) 34 (92) 31 (91)
Surgery 13 (36) 10 (27) 7 (20) 8 (24) 11 (30) 9 (26)
Radiotherapy 10 (28) 10 (27) 6 (17) 8 (24) 14 (38) 10 (29)
ESA 0 2 (5) 1 (3) 0 1 (3) 2 (6)
Hb level, g/dL (range) 10.2 (7.1–13.9) 10.2 (8.1–12.8) 10.3 (3.5–12.7) 10.4 (6.8–13.3) 10.1 (8.0–12.9) 10.6 (8.0–14.0)
Serum ferritin level, ng/mL (range) 350 (55–2188) 439 (48–1231) 285 (65–1403) 502 (92–1718) 472 (90–1225) 507 (79–1561)
C.E.R.A.: Continuous Erythropoietin Receptor Activator.
ESA: erythropoiesis-stimulating agent.
Hb: hemoglobin.
QW: once weekly.
Q3W: once every 3 weeks.Trials 2007, 8:8 http://www.trialsjournal.com/content/8/1/8
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Frequency of blood transfusions per patient Figure 2
Frequency of blood transfusions per patient. (A) Group administered C.E.R.A. once weekly. (B) Group administered 
C.E.R.A. once every 3 weeks. Intent-to-treat population. 
C.E.R.A.: Continuous Erythropoietin Receptor Activator. 
QW: once weekly. 
Q3W: once every three weeks.
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tion, as the numbers of patients in each group were small,
particularly in the 2.1 μg/kg group (one patient with 'early
response', 14 with 'no response').
Pharmacokinetics
Pharmacokinetic parameters following SC administration
of C.E.R.A. QW and Q3W are summarized in Table 4.
Median Tmax values were 70–74 hours (3 days) in the QW
group and 82–120 hours (3–5 days) in the Q3W group.
Mean Cmax  and AUC22–29 days or AUC22–43 days values
increased with increasing C.E.R.A. dose in both the QW
and Q3W groups. In the Q3W group, due to low clearance
(median values 34.7–49.4 mL/h/kg), mean t1/2  values
were long, ranging from 6.5–7.8 days. The C.E.R.A. half-
life could not be determined in the QW group because of
low patient numbers (n = 4, 2, 3 in the 0.7, 1.4, and 2.1
μg/kg groups, respectively). The mean C.E.R.A. serum
concentrations over time in the Q3W group are shown in
Figure 4.
Tolerability and safety
C.E.R.A. dose modification (dose reduced or withheld)
was more frequent in the QW group compared with the
Q3W group, probably because of the larger number of
opportunities to change dose in the QW group. There did
not appear to be a dose-related trend. In the QW group,
six (17%), 14 (38%), and 15 (43%) patients in the 0.7,
1.4, and 2.1 μg/kg groups, respectively, had C.E.R.A. dose
modifications. In the Q3W group, five (15%), 11 (30%),
and nine (27%) patients in the 2.1, 4.2, and 6.3 μg/kg
groups, respectively, had dose modifications.
C.E.R.A. doses of 0.7, 1.4, or 2.1 μg/kg given QW and 2.1,
4.2, or 6.3 μg/kg given Q3W were generally well tolerated.
The QW and Q3W groups showed similar tolerability pro-
Proportions of early, additional, and non-responders in group administered C.E.R.A. once every 3 weeks Figure 3
Proportions of early, additional, and non-responders in group administered C.E.R.A. once every 3 weeks. 
Intent-to-treat population. 'Early responders': patients with a ≥ 1 g/dL increase in hemoglobin (Hb) from baseline during the 
first 22 days, with no concomitant blood transfusion during the study. 
'Additional responders': patients who were not early responders but achieved the target therapeutic range of 11–13 g/dL dur-
ing the study without blood transfusion. 
'Non-responders': patients who did not qualify as early responders or additional responders. 
C.E.R.A.: Continuous Erythropoietin Receptor Activator. 
Q3W: once every three weeks.
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files (Table 5). The proportion of patients reporting
adverse events was similar across all treatment groups.
Events were reported by 89%, 97%, and 94% in the 0.7,
1.4, and 2.1 μg/kg QW groups, respectively, and in 94%,
95%, and 97% of patients in the 2.1, 4.2, and 6.3 μg/kg
Q3W groups, respectively. The most frequently reported
adverse events were nausea, fatigue, anorexia, vomiting,
and neutropenia (Table 5), and were most likely second-
ary to chemotherapy. There did not appear to be a dose-
related trend in the incidence of events.
There were 13 and 14 deaths in the QW and Q3W dose
groups, respectively, none of which was considered by the
investigator to be related to the study medication. Six and
four patients in the QW (5.6%) and Q3W dose group
(3.8%), respectively, had adverse events that were consid-
ered by the investigator to be related to study treatment.
In the 0.7 μg/kg QW group, one patient had four adverse
events considered related to treatment (back pain, ane-
mia, neutropenia, and hypersensitivity), one patient expe-
rienced injection site pain, one patient had pyrexia, and
one patient had bone pain. In the 1.4 and 2.1 μg/kg QW
groups, one patient in each group had thrombophlebitis.
In the 2.1 μg/kg Q3W group, one patient had injection
site discomfort; in the 4.2 μg/kg Q3W group, one patient
experienced flushing, hypertension, and headache, and
another patient had bruising at the injection site; in the
6.3  μg/kg Q3W group, one patient was reported with
atrial fibrillation. Of these patients, only the patient with
atrial fibrillation withdrew from the study due to the
adverse event. The patient was hospitalized and treated
with digoxin 0.25 mg. Normal sinus rhythm was restored
soon after admission, although second degree atrioven-
tricular heart block was recorded. Four other adverse
events led to premature withdrawal from the study in the
Q3W dose group (two in the 2.1 μg/kg group and two in
the 6.3 μg/kg group). The reasons for withdrawal were
brain metastasis (one patient) and NSCLC progression
(three patients). In the QW group, eight adverse events led
to premature withdrawal (three in the 0.7 μg/kg group,
three in the 1.4 μg/kg group, and two in the 2.1 μg/kg
group). The reasons for withdrawal were NSCLC progres-
sion (five patients), renal failure (one patient), worsening
of anemia (one patient), and hemoptysis (one patient).
Three patients in the QW group (2.8%; two in the 1.4 μg/
kg group and one in the 2.1 μg/kg group) and two patients
in the Q3W group (1.9%; both in the 4.2 μg/kg group)
had thrombovascular events (TVEs), including throm-
botic events. In the Q3W group, myocardial infarction
was reported in one patient and cerebrovascular accident
in another. None of the TVEs were considered by the
investigator to be related to treatment with C.E.R.A. No
TVEs were reported in the 6.3 μg/kg Q3W group.
There were no clinically significant changes from baseline
in laboratory values and vital signs during the study in all
dose groups, or dose-dependent relationships for increas-
ing blood pressure. In addition, no anti-C.E.R.A. antibod-
ies were detected.
Table 4: Pharmacokinetic values for C.E.R.A. after subcutaneous injection. Results are given as mean ± SD, apart from Tmax and CL/F, 
which are given as median values.
C.E.R.A. dose group, μg/kg (n) Cmax (ng/mL) Tmax (h) AUC (ng • h/mL)* t1/2 (h) CL/F (mL/h/kg)
QW
0.7 (14) 6.7 ± 2.5 71 931 ± 358 171 ± 69† 25.3
1.4 (16) 10.6 ± 4.1 74 1355 ± 548‡ NC** 25.1
2.1 (15) 20.2 ± 8.7 70 2709 ± 1193 212 ± 200† 23.4
Q3W
2.1 (18) 8.2 ± 3.8 120 2750 ± 1318 157 ± 38† 34.7
4.2 (18) 16.6 ± 9.5 82 4651 ± 2569‡ 174 ± 44† 42.8
6.3 (17) 20.9 ± 12.5 120 6547 ± 3957‡ 186 ± 78† 49.4
AUC: area under the serum concentration-time curve.
C.E.R.A.: Continuous Erythropoietin Receptor Activator.
CL: clearance.
Cmax: maximum serum concentration.
F: bioavailability.
QW: once weekly.
Q3W: once every 3 weeks.
SD: standard deviation.
Tmax: time to Cmax.
t1/2: terminal half-life.
*AUC22–29 days for QW group and AUC22–43 days for Q3W group.
**NC, not calculated (n = 2).
†n = 4 and 3 in 0.7 and 2.1 QW groups, respectively, and n = 11, 15, 14 in 2.1, 4.2, and 6.3 Q3W groups, respectively.
‡n = 15, 16, and 14 for 1.4 QW. 4.2 Q3W, and 6.3 Q3W groups, respectively.Trials 2007, 8:8 http://www.trialsjournal.com/content/8/1/8
Page 11 of 15
(page number not for citation purposes)
Discussion
Treatment with ESAs is now the standard of care for chem-
otherapy-induced anemia, resulting in increased Hb lev-
els, reduced transfusion requirements, and improved QoL
[18-22]. However, new treatments that allow less frequent
administration and coordination of administration with
chemotherapy regimens, and with improved early and
sustained Hb response, would further improve the clinical
profile of ESAs. C.E.R.A. is the first continuous erythropoi-
etin receptor activator developed for the control of ane-
mia in patients with cancer. In preclinical studies and
healthy volunteers, C.E.R.A. was shown to have a pro-
longed serum half-life, suggesting that it may be adminis-
tered at extended intervals when compared with ESAs
[28,29]. A small study in patients with multiple myeloma
demonstrated dose-dependent increases in maximum
C.E.R.A. serum concentration and Hb levels over a 6-week
treatment period using Q3W administration and doses up
Table 5: Most frequently reported adverse events (in ≥ 5% of patients in any treatment group). Patients administered C.E.R.A. QW or 
Q3W.
C.E.R.A. dose group (μg/kg QW) C.E.R.A. dose group (μg/kg Q3W)
Adverse event, n (%) 0.7 (n = 36) 1.4 (n = 37) 2.1 (n = 35) 2.1 (n = 34) 4.2 (n = 37) 6.3 (n = 34)
Nausea 12 (33) 6 (16) 11 (31) 11 (32) 7 (19) 4 (12)
Fatigue 11 (31) 8 (22) 7 (20) 6 (18) 10 (27) 7 (21)
Anorexia 7 (19) 7 (19) 7 (20) 6 (18) 7 (19) 6 (18)
Vomiting 8 (22) 7 (19) 9 (26) 6 (18) 2 (5) 6 (18)
Neutropenia 9 (25) 3 (8) 6 (17) 8 (24) 7 (19) 4 (12)
Asthenia 5 (14) 5 (14) 5 (14) 6 (18) 5 (14) 4 (12)
Cough 8 (22) 3 (8) 3 (9) 5 (15) 4 (11) 4 (12)
Diarrhea 6 (17) 5 (14) 4 (11) 3 (9) 6 (16) 3 (9)
C.E.R.A.: Continuous Erythropoietin Receptor Activator.
QW: once weekly.
Q3W: once every 3 weeks.
Mean serum concentration-time profiles for C.E.R.A. after subcutaneous injection once every 3 weeks Figure 4
Mean serum concentration-time profiles for C.E.R.A. after subcutaneous injection once every 3 weeks. 
C.E.R.A.: Continuous Erythropoietin Receptor Activator. 
Q3W: once every three weeks.
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to 8 μg/kg [27]. In addition, the proportion of patients
with a Hb response in patients treated with C.E.R.A. 3.5–
8.0 μg/kg (50.0%–62.5%) compared favorably with val-
ues obtained in studies of epoetin beta and darbepoetin
alfa given QW in cancer patients receiving myelosuppres-
sive chemotherapy [19,31]. The present study examined
the efficacy, safety, and pharmacokinetic profile of
C.E.R.A. in anemic patients with Stage IIIB or IV NSCLC
receiving myelosuppressive chemotherapy. The dose
range chosen was based on the doses shown to be effective
in the multiple myeloma study [27]. In this study, patients
with NSCLC receiving chemotherapy were administered
one of six doses of C.E.R.A. (0.7–2.1 μg/kg QW or 2.1–6.3
μg/kg Q3W) by SC injection.
The results demonstrated that C.E.R.A. treatment led to
dose-related improvements in patients' anemia. Increases
in mean Hb level and Hb response were observed with
increasing doses of C.E.R.A. administered Q3W and QW.
Dose-dependent increases in Hb were also observed when
the change from baseline during week 5 to week 13 was
assessed; but it is important to achieve more substantial
erythropoietic benefits, which could be observed with
higher doses of C.E.R.A. It is also interesting to note that,
although the study was not powered to compare dose
schedules, there was an inclination for higher increases in
mean Hb level overall and during week 5 to week 13 when
the same dose over time was given Q3W rather than QW.
The majority of patients in the 4.2 and 6.3 μg/kg Q3W
groups (51% and 62%, respectively) and 2.1 μg/kg QW
group (63%) achieved a hematopoietic response. In addi-
tion, in the Q3W group, the proportion of 'early
responder' patients increased with increasing C.E.R.A.
dose, reaching 41% with the highest dose. Adding
together the proportions of 'early responders' and 'addi-
tional responders', the total response in the 6.3 μg/kg
group was 82%. Conversely, the proportion of patients
who did not respond to C.E.R.A. treatment decreased with
increasing C.E.R.A. dose. There was also an indication that
early response was predictive of later Hb increases. The
magnitude of mean Hb increase during weeks 5–13 was
higher in 'early responders' than in patients who did not
show early response.
The majority of patients in all six treatment groups did not
require blood transfusion during the study. There was a
trend for a greater transfusion-saving effect with C.E.R.A.
administered Q3W compared with QW treatment; 60% of
patients in the 2.1 μg/kg QW group did not require trans-
fusion in comparison with 85% of patients administered
the same weekly dose Q3W (6.3 μg/kg Q3W). Also, in the
6.3  μg/kg Q3W group, of the 15% of patients that
required blood transfusion, all received only one transfu-
sion during the study. This suggests a positive drug effect,
as previous studies suggested a very high rate (up to 59%)
of transfusion use in patients with lung cancer receiving
platinum therapy without the support of an ESA [32,33].
The major limitations of the current study design included
the lack of a placebo or active control group in the study,
the limited range of C.E.R.A. doses, and the lack of dose
increase in the event of an inadequate Hb response. Most
other studies of ESAs in patients with lung cancer allowed
dose increases in patients who did not respond [20,34-
36]. Despite this, the Hb and hematopoietic response
rates from this study compare well with those from stud-
ies of ESA treatment of anemia in patients with lung can-
cer receiving chemotherapy. In a study of darbepoetin alfa
QW treatment, the proportion of patients with a hemat-
opoietic response (defined as an increase in Hb of ≥ 2.0 g/
dL or Hb ≥ 12 g/dL in the absence of transfusion in the
previous 28 days) was 66% [20]. This response rate was
similar to the 62% hematopoietic response rate achieved
in the C.E.R.A. 6.3 μg/kg Q3W group in the present study.
However, a more stringent definition of response was
applied in the current study (confirmed on two consecu-
tive measurements in this study versus a single measure-
ment in the darbepoetin alfa study). Also, nearly half of
patients (43%) in the darbepoetin alfa study required
dose doubling to 4.5 μg/kg QW because of inadequate
response to 2.25 μg/kg QW [20,37]. Therefore, it is rea-
sonable to hypothesize that response rates in the present
study could have been even higher if dose increases had
been permitted.
Despite the presence of some similarities with other stud-
ies, one has to be careful when comparing the results of
the present study with those of some previous trials of ESA
treatment in lung cancer. Most previous ESA studies
included a mixture of patients with small cell lung cancer
and NSCLC [20,34-36,38-40] in contrast to this study
which included only Stage IIIB or IV NSCLC patients.
Other factors compromising between-study comparisons
include differences in patient populations in terms of dis-
ease stages and chemotherapy intensity. In terms of dis-
ease stage, a study of darbepoetin alfa 200 μg every 2
weeks and epoetin alfa 40,000 IU QW examined the
hematopoietic response in patients with breast, gyneco-
logic, or Stage IIIB/IV NSCLC [36]. The mean change from
baseline Hb at the end of treatment (up to 16 weeks) was
lowest in patients with advanced NSCLC: 0.6 and 1.3 g/dL
in the darbepoetin alfa and epoetin alfa groups, respec-
tively, in comparison with increases of 1.7–1.9 g/dL or 1.3
g/dL in patients with breast cancer or gynecologic cancer.
The late disease stage was thought to have contributed to
the poorer responses in the NSCLC patients [36]. Also, the
intensity of chemotherapy varied in previous studies of
patients with Stage III/IV NSCLC [20,35,36,39]. In the
present study, most patients had received chemotherapyTrials 2007, 8:8 http://www.trialsjournal.com/content/8/1/8
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before the study and all received chemotherapy during the
study, most commonly platinum based (65% to 91%).
The use of platinum compounds has been shown to have
a negative impact on Hb levels in patients with lung can-
cer [5].
The pharmacokinetic profile of C.E.R.A., including a pro-
longed half-life and low clearance, is different to that of
epoetin alfa and darbepoetin alfa [26]. The half-life of
C.E.R.A. was considerably longer than that of the ESAs.
Epoetin alfa has a half-life of approximately 40–44 hours
in cancer patients [41,42] and approximately 19 hours in
healthy volunteers [43]. Darbepoetin alfa has a half-life of
39–74 hours in cancer patients [44,45] and 49 hours in
patients with kidney disease [46]. The t1/2 (mean 157–186
hours) of C.E.R.A. reported in this study was similar to the
values observed in patients with multiple myeloma [27],
healthy volunteers [29], and renal patients [47].
C.E.R.A. administered Q3W and QW with concomitant
chemotherapy was generally well tolerated across all dose
groups. The adverse events reported were mainly related
to the effects of chemotherapy or the underlying disease.
The incidences of fatigue, anorexia, and dyspnea were
similar to those reported in the darbepoetin alfa trial of
lung cancer patients [20], whereas the incidence of nau-
sea, most likely related to chemotherapy, appeared to be
lower in the C.E.R.A. study (12%–33% versus approxi-
mately 42%). On the other hand, in a retrospective analy-
sis of three epoetin alfa lung cancer studies, the incidence
of adverse events was lower than in the C.E.R.A. study
[34]. These different findings may be explained by dose
non-comparability and methodological differences
between the separate studies, making direct comparisons
difficult. TVEs were reported by three patients in the QW
group (two in the 1.4 μg/kg dose group and one in the 2.1
μg/kg dose group) and two patients in the Q3W group
(4.2 μg/kg dose group). There were no TVEs in the 6.3 μg/
kg dose Q3W group. All TVEs were considered to be unre-
lated to C.E.R.A. by the investigator. This TVE incidence is
similar to that reported with placebo treatment in meta-
analyses of ESA studies [48,49].
Conclusion
The Hb results in this study show that C.E.R.A. adminis-
tered SC QW or Q3W has clinical activity in patients with
Stage IIIB (pleural effusion) or IV NSCLC. There were
dose-dependent and sustained increases in response
related to Hb level with increasing C.E.R.A. dose levels on
QW and Q3W dosing schedules. The proportion of
patients with early responses also increased with increas-
ing C.E.R.A. dose administered Q3W, reaching 41% in the
6.3 μg/kg group. There was an inclination for improved
effectiveness of C.E.R.A. in terms of mean Hb level
increases and transfusion use when the same dose over
time was given Q3W as opposed to QW. In the 6.3 μg/kg
Q3W group, most patients remained transfusion-free
(85%) during the study, with no patients in the 6.3 μg/kg
group requiring more than one transfusion. C.E.R.A. was
generally well tolerated across all dose groups. These
results suggest that C.E.R.A. Q3W has the potential to
reduce the burden of anemia management for patients
and healthcare providers by providing an effective alterna-
tive to transfusions in a treatment that can be synchro-
nized with a patient's chemotherapy regimen.
Confirmation of the previously defined pharmacokinetic
profile of C.E.R.A., and its good tolerability and safety
profile in this study of patients with advanced NSCLC,
also suggest that extended administration intervals are
feasible in the clinic. However, further dose-finding stud-
ies that use higher doses and allow dose escalation are
required to determine the optimal C.E.R.A. Q3W dose reg-
imen in anemic cancer patients receiving chemotherapy.
The results of other studies with C.E.R.A. in the treatment
of chemotherapy-related anemia are awaited.
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